| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00276744 Details | 2018-10-24 Interventional | 2 | 249 | Capecitabine Cetuximab Docetaxel Erlotinib Hydro… Gemcitabine Irinotecan Mitomycin Mitomycins Sirolimus Pancreatic Neop… Pancreatic Canc… | Because there was no longer an active laboratory component to this study. - | |||
| NCT02972502 Details | 2018-10-23 Interventional | 4 | 66 | Diphenhydramine Haloperidol Haloperidol dec… Metoclopramide Promethazine Emergencies Headache Migraine Disord… Headache, Migra… | PI lapsed institutional training This study was terminated by the IRB due to PI lapse in required training. Outcomes data reported includes preliminary figures for n=49 patients. Data not collected from 11 patients. | |||
| NCT02500927 Details | 2018-10-23 Interventional | 2 | 31 | Naquotinib Carcinoma, Non-… Lung Neoplasms EGFR-TKI-naïve… | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. - | |||
| NCT02929576 2016-000796-25 Details | 2018-10-22 Interventional | 3 | 0 | Paclitaxel Breast Neoplasm… Triple Negative… Breast Cancer | Further understanding about the role of androgen signaling in TNBC was required - | |||
| NCT02850744 Details | 2018-10-19 Interventional | 2 | 10 | Temozolomide Glioblastoma Glioblastoma Mu… | - - | |||
| NCT01185548 Details | 2018-10-19 Interventional | 1 | 4 | Tolbutamide Lymphoma Advanced Cancer | Terminated based on safety results from another trial - | |||
| NCT02739477 Details | 2018-10-18 Interventional | 2 | 2 | Favipiravir Hemorrhagic Fev… Ebola Virus Sur… | End date of epidemic - | |||
| NCT01917006 2013-001650-94 Details | 2018-10-18 Interventional | 2 | 59 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Premature Birth Premature Ejacu… | Strategic business decision was made to terminate the program. There were no safety concerns. - | |||
| NCT01944969 2012-004169-42 Details | 2018-10-17 Interventional | 3 | 26 | Brexpiprazole Depression Depressive Diso… Depressive Diso… Major Depressiv… | The study was terminated because the lead-in study (14571A) in elderly was terminated; see
Detailed Description. Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety. | |||
| NCT00874939 Details | 2018-10-17 Interventional | 1 | 4 | Donepezil Alzheimer Disea… Alzheimer's Dis… Dementia | - - | |||
| NCT03707678 Details | 2018-10-16 Interventional | 2 | 0 | Albuterol Asthma | After careful review of new data on GSK2245035, GlaxoSmithKline has decided to cancel this
study. - | |||
| NCT03020563 Details | 2018-10-16 Interventional | 4 | 0 | Bupivacaine Fractures, Bone Clavicle Fractu… | no longer necessary - | |||
| NCT02592629 Details | 2018-10-16 Interventional | 4 | 19 | Ethyl Chloride Lidocaine Triamcinolone Triamcinolone A… Shoulder Pain | Lack of time to enroll due to additional responsibilities of the PI and research coordinator. - | |||
| NCT02474407 Details | 2018-10-16 Interventional | 2 | 78 | Diazepam Drug Resistant … Epilepsy Refractory Epil… | - - | |||
| NCT02469415 Details | 2018-10-16 Interventional | 2 | 3 | Azacitidine Decitabine Myelodysplastic… Preleukemia Leukemia | FDA Clinical Hold - | |||
| NCT01602679 Details | 2018-10-16 Interventional | 1 | 12 | Progesterone Female Reproduc… | Interim analysis suggested futility. - | |||
| NCT03191383 2016-002733-30 Details | 2018-10-15 Interventional | 2 | 0 | Vaccines Respiratory Syn… | Study was canceled due to instability of the PreF antigen during manufacturing. No safety
concern has been identified in past or ongoing studies. - | |||
| NCT02138812 Details | 2018-10-12 Interventional | 1 | 69 | Paclitaxel Neoplasms Medical Oncolog… | As another Mps1 inhibitor was being developed in parallel, the strategic decision was to move
forward with the development of the follow up compound only. - | |||
| NCT01956474 Details | 2018-10-12 Interventional | 2 | 1324 | Riboflavin Keratoconus | - - | |||
| NCT00132730 Details | 2018-10-12 Interventional | 2 | 604 | MK 0873 Lung Diseases Pulmonary Disea… | - The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD. |